EUVIMEDEUVIMED entdecken
Fallbericht

Molecular characterization of borderline and malignant Brenner tumors: implications for pathogenesis and therapeutics

Yao Sun, Haiyan Shi, Bingjian Lu

Pathology - Research and Practice · 2026-06 · 282 · 156446

DOI: 10.1016/j.prp.2026.156446 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pathology - Research and Practice, 2026-06. Verfasst von Yao Sun und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Pathology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China. Electronic address: …. Hauptthemen laut MEDLINE: Brenner Tumor, Ovarian Neoplasms, Biomarkers, Tumor, Adenocarcinoma, Mucinous. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian borderline (BrBT) and malignant (MBT) Brenner tumors are rare neoplasms frequently exhibiting mucinous metaplasia, yet their molecular drivers are poorly defined. To address this, we performed a clinicopathological and molecular study on two cases each BrBT and MBT by immunohistochemistry, fluorescence in situ hybridization, and next-generation sequencing. Recurrent alterations included CDKN2A/CDKN2B deletion with loss of p16 (3/4 cases), MDM2 amplification with positive immunostaining (2/4), and mutations in KRAS, PIK3CA, and FGFR3. A unique MBT with concurrent mucinous adenocarcinoma harboring KRAS/PIK3CA co-mutations followed an aggressive, fatal course. Our analysis and a synthesis of the literature confirm that CDKN2A/CDKN2B deletion and PIK3CA mutation are common in both BrBT and MBT, while MDM2 amplification and KRAS/FGFR3 alterations are enriched in MBT. These findings delineate key molecular drivers, reveal therapeutic vulnerabilities, and underscore the need for molecular-guided strategies in these rare tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brenner TumorOvarian NeoplasmsBiomarkers, TumorAdenocarcinoma, MucinousHumansFemaleMutationProto-Oncogene Proteins p21(ras)Middle AgedReceptor, Fibroblast Growth Factor, Type 3Class I Phosphatidylinositol 3-Kinases

Stichwörter der Autor:innen

BorderlineBrenner tumorMalignantMucinous tumorMutation

Substanzen

Biomarkers, TumorProto-Oncogene Proteins p21(ras)Receptor, Fibroblast Growth Factor, Type 3KRAS protein, humanClass I Phosphatidylinositol 3-KinasesPIK3CA protein, human

Autor:innen und Institutionen

  • Department of Surgical Pathology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China. Electronic address: 5513046@zju.edu.cn.
  • Department of Surgical Pathology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China. Electronic address: shihy1991@zju.edu.cn.
  • Department of Surgical Pathology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China; Zhejiang Provincial Key Laboratory of Precision Diagnosis and Therapy for Major Gynecologi…

Zitieren

APA

Sun, Y., Shi, H., & Lu, B. (2026). Molecular characterization of borderline and malignant Brenner tumors: implications for pathogenesis and therapeutics. Pathology - Research and Practice, 282, 156446. https://doi.org/10.1016/j.prp.2026.156446

Vancouver

Sun Y, Shi H, Lu B. Molecular characterization of borderline and malignant Brenner tumors: implications for pathogenesis and therapeutics. Pathology - Research and Practice. 2026;282:156446. doi:10.1016/j.prp.2026.156446

BibTeX
@article{Sun2026,
  author = {Sun, Yao and Shi, Haiyan and Lu, Bingjian},
  title = {Molecular characterization of borderline and malignant Brenner tumors: implications for pathogenesis and therapeutics},
  journal = {Pathology - Research and Practice},
  year = {2026},
  volume = {282},
  pages = {156446},
  doi = {10.1016/j.prp.2026.156446}
}
Kostenlos starten →